Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multi-Centre, Randomised, Open-Label, Controlled Trial Evaluating the Efficacy and Safety of Prophylactic Administration of Concizumab in Haemophilia A and B Patients with Inhibitors

Next Previous
Trial Profile

A Multi-Centre, Randomised, Open-Label, Controlled Trial Evaluating the Efficacy and Safety of Prophylactic Administration of Concizumab in Haemophilia A and B Patients with Inhibitors

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 06 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Concizumab (Primary) ; Eptacog alfa (Primary)
  • Indications Haemophilia A; Haemophilia B
  • Focus Therapeutic Use
  • Acronyms explorer™4
  • Sponsors Novo Nordisk

    • Most Recent Events

    • 06 Nov 2019 Results of Efficacy and Safety of Subcutaneous Prophylaxis with Concizumab in Patients with Hemophilia a or B with Inhibitors, explorer4 study released at the 61st Annual Meeting and Exposition of the American Society of Hematology
    • 06 Nov 2019 Results evaluating Health-Related Quality-of-Life Measures released at the 61st Annual Meeting and Exposition of the American Society of Hematology.
    • 06 Nov 2019 Data were used from two clinical studies; Explore 4 (n=16) and Explore 5 (n=30) to assess the addictive effects of combination of concizumab and bypassing agents recombinant activated factor VII (rFVIIa) or activated prothrombin complex concentrate (aPCC), released in 61st Annual Meeting and Exposition of the American Society of Hematology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top